Immediate in vivo target-specific cancer cell death after near infrared photoimmunotherapy

BMC Cancer

Hisataka Kobayashi¹  Peter L Choyke¹  Gabriela Kramer-Marek²  Kohei Sano¹  Takahito Nakajima¹  Makoto Mitsunaga¹ 

[1]Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Room B3B69, MSC1088, Bethesda, MD, 20892-1088, USA

[2]Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA

关键词: Bioluminescence imaging;    Monoclonal antibody;    Molecular targeting;    Epidermal growth factor receptor;    Cell death;    Theranostics;    Photoimmunotherapy;   

Others  :  1080263
DOI  :  10.1186/1471-2407-12-345

 received in 2012-05-22, accepted in 2012-07-31,  发布年份 2012

【 摘 要 】

Background

Near infrared (NIR) photoimmunotherapy (PIT) is a new type of cancer treatment based on a monoclonal antibody (mAb)-NIR phthalocyanine dye, (IR700) conjugate. In vitro cancer-specific cell death occurs during NIR light exposure in cells previously incubated with mAb-IR700 conjugates. However, documenting rapid cell death in vivo is more difficult.

Methods

A luciferase-transfected breast cancer cell (epidermal growth factor receptor+, MDA-MB-468luc cells) was produced and used for both in vitro and in vivo experiments for monitoring the cell killing effect of PIT. After validation of cytotoxicity with NIR exposure up to 8 J/cm²in vitro, we employed an orthotopic breast cancer model of bilateral MDA-MB-468luc tumors in female athymic mice, which subsequently received a panitumumab-IR700 conjugate in vivo. One side was used as a control, while the other was treated with NIR light of dose ranging from 50 to 150 J/cm². Bioluminescence imaging (BLI) was performed before and after PIT.

Results

Dose-dependent cell killing and regrowth was successfully monitored by the BLI signal in vitro. Although tumor sizes were unchanged, BLI signals decreased by >95% immediately after PIT in vivo when light intensity was high (>100 J/cm²), however, in mice receiving lower intensity NIR (50 J/cm²), tumors recurred with gradually increasing BLI signal.

Conclusion

PIT induced massive cell death of targeted tumor cells immediately after exposure of NIR light that was demonstrated with BLI in vivo.

【 授权许可】

   
2012 Mitsunaga et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1 .

Figure 2 .

Figure 3 .

Figure 4 .

【 参考文献 】

• [1]Waldmann TA: Immunotherapy: past, present and future. Nat Med 2003, 9:269-277.
• [2]Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ: Immunotoxin therapy of cancer. Nat Rev Cancer 2006, 6:559-565.
• [3]Mitsunaga M, Ogawa M, Kosaka N, Rosenblum LT, Choyke PL, Kobayashi H: Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules. Nat Med 2011, 17:1685-1691.
• [4]Mitsunaga M, Nakajima T, Sano K, Choyke PL, Kobayashi H: Near-infrared theranostic photoimmunotherapy (PIT): repeated exposure of light enhances the effect of immunoconjugate. Bioconjug Chem 2012, 23:604-609.
• [5]Contag PR, Olomu IN, Stevenson DK, Contag CH: Bioluminescent indicators in living mammals. Nat Med 1998, 4:245-247.
• [6]Rehemtulla A, Stegman LD, Cardozo SJ, Gupta S, Hall DE, Contag CH, Ross BD: Rapid and quantitative assessment of cancer treatment response using in vivo bioluminescence imaging. Neoplasia 2000, 2:491-495.
• [7]Dothager RS, Flentie K, Moss B, Pan MH, Kesarwala A, Piwnica-Worms D: Advances in bioluminescence imaging of live animal models. Curr Opin Biotechnol 2009, 20:45-53.
• [8]Lyakhov I, Zielinski R, Kuban M, Kramer-Marek G, Fisher R, Chertov O, Bindu L, Capala J: HER2- and EGFR-specific affiprobes: novel recombinant optical probes for cell imaging. ChemBioChem 2010, 11:345-350.
• [9]Leist M, Single B, Castoldi AF, Kuhnle S, Nicotera P: Intracellular adenosine triphosphate (ATP) concentration: a switch in the decision between apoptosis and necrosis. J Exp Med 1997, 185:1481-1486.
• [10]Zamaraeva MV, Sabirov RZ, Maeno E, Ando-Akatsuka Y, Bessonova SV, Okada Y: Cells die with increased cytosolic ATP during apoptosis: a bioluminescence study with intracellular luciferase. Cell Death Differ 2005, 12:1390-1397.
• [11]McNeil PL, Steinhardt RA: Plasma membrane disruption: repair, prevention, adaptation. Annu Rev Cell Dev Biol 2003, 19:697-731.
• [12]Hoffman RM: The multiple uses of fluorescent proteins to visualize cancer in vivo. Nat Rev Cancer 2005, 5:796-806.
• [13]Hoffman RM, Yang M: Subcellular imaging in the live mouse. Nat Protoc 2006, 1:775-782.
• [14]Jiang P, Yamauchi K, Yang M, Tsuji K, Xu M, Maitra A, Bouvet M, Hoffman RM: Tumor cells genetically labeled with GFP in the nucleus and RFP in the cytoplasm for imaging cellular dynamics. Cell Cycle 2006, 5:1198-1201.
• [15]Yamamoto N, Jiang P, Yang M, Xu M, Yamauchi K, Tsuchiya H, Tomita K, Wahl GM, Moossa AR, Hoffman RM: Cellular dynamics visualized in live cells in vitro and in vivo by differential dual-color nuclear-cytoplasmic fluorescent-protein expression. Cancer Res 2004, 64:4251-4256.
• [16]Kimura H, Lee C, Hayashi K, Yamauchi K, Yamamoto N, Tsuchiya H, Tomita K, Bouvet M, Hoffman RM: UV light killing efficacy of fluorescent protein-expressing cancer cells in vitro and in vivo. J Cell Biochem 2010, 110:1439-1446.
• [17]Tsai MH, Aki R, Amoh Y, Hoffman RM, Katsuoka K, Kimura H, Lee C, Chang CH: GFP-fluorescence-guided UVC irradiation inhibits melanoma growth and angiogenesis in nude mice. Anticancer Res 2010, 30:3291-3294.
• [18]Shimomura O: Discovery of green fluorescent protein (GFP) (Nobel Lecture). Angew Chem Int Ed Engl 2009, 48:5590-5602.
• [19]Hoffman RM: Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Invest New Drugs 1999, 17:343-359.